CureVac COVID-19 vaccine records only 48% efficacy in final trial readout – Reuters
A dose of CureVac vaccine or a placebo is seen during a study by the German biotech firm CureVac as part of a testing for a new vaccine against the coronavirus disease (COVID-19), in Brussels, Belgium March 2, 2021. REUTERS/Yves Herman
June 30 (Reuters)…
